Regenxbio stock rating reiterated at Buy by H.C. Wainwright on positive trial data

Regenxbio Inc. (RGNX) reported robust 12-month data for its Hunter syndrome gene therapy, RGX-121, demonstrating an 82% median reduction in a key biomarker and positive neurodevelopmental outcomes, reinforcing its Biologics License Application with the FDA. Despite the FDA extending the PDUFA goal date to February 2026 for additional data review, analysts like H.C. Wainwright and Raymond James maintain positive ratings, citing the strong clinical profile and anticipating significant revenue growth exceeding 200% for FY2025, which has already driven RGNX shares up over 53% in six months.

Analysis

Regenxbio Inc. (RGNX) has significantly de-risked its lead asset, clemidsogene lanparvovec (RGX-121), with new 12-month pivotal data from the CAMPSIITE trial. The results demonstrated a sustained 82% median reduction in cerebrospinal fluid levels of a key biomarker (heparan sulfate D2S6, p<0.0001) for Mucopolysaccharidosis II, meeting the trial's primary endpoint. Importantly, this biomarker reduction showed a strong correlation with neurodevelopmental skill acquisition or stability, bolstering the therapy's clinical value proposition. In response, Regenxbio has submitted this data to the FDA as part of its ongoing Biologics License Application review. While the FDA has extended the PDUFA goal date to February 8, 2026, to review the longer-term data, the agency's pre-license and bioresearch inspections in August 2025 concluded with no observations, a positive signal for the application's quality. The market has already reacted favorably, with RGNX shares surging over 53% in the past six months. Analyst sentiment is largely positive but divergent, with H.C. Wainwright reiterating a 'Buy' rating ($34 target) and Raymond James an 'Outperform' ($29 target), while Goldman Sachs maintains a 'Neutral' rating ($14 target), reflecting a wide range of valuation outcomes. The bullish case is further supported by a forecast for revenue growth to exceed 200% in fiscal year 2025.

Key Decisions for Investors

• Investors should weigh the strong probability of approval for RGX-121, supported by robust clinical data and a clean FDA inspection record, against the significant share price appreciation of over 53% in the last six months.
• The PDUFA date extension to February 2026 is a key event to monitor; while the delay is for review of positive long-term data, it pushes out the primary catalyst and introduces additional timeline risk.
• Given the wide dispersion in analyst price targets from $14 to $52, it may be prudent to consider the stock's volatility and await further clarity on the regulatory pathway or potential commercialization strategy before establishing a full position.